1. COVID-19 in patients with cancer: Risks and precautions.
- Author
-
Razavi A, Hamblin MR, and Rezaei N
- Subjects
- COVID-19 complications, COVID-19 immunology, Cytokine Release Syndrome immunology, Disease Susceptibility, Hematologic Neoplasms complications, Hematologic Neoplasms immunology, Hematologic Neoplasms physiopathology, Hematologic Neoplasms therapy, Humans, Immunocompromised Host, Immunotherapy, Adoptive adverse effects, Lung Neoplasms complications, Lung Neoplasms immunology, Lung Neoplasms physiopathology, Lung Neoplasms therapy, Neoplasms complications, Neoplasms immunology, Neoplasms therapy, Receptors, Chimeric Antigen, SARS-CoV-2, Severity of Illness Index, T-Lymphocytes immunology, COVID-19 physiopathology, Neoplasms physiopathology
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the coronavirus family, which causes coronavirus disease 2019 (COVID-19). The phenotype of the disease varies from asymptomatic, to a mild phenotype, through to the severe form of acute respiratory distress syndrome (ARDS), which often leads to death, especially in those with underlying diseases. It has been reported that those who suffer from cancer (especially lung cancer and hematological malignancies) are at higher risk of serious complications and death from COVID-19. Some cancer treatments such as CAR T cell therapy can produce a cytokine storm, which is also a hallmark of severe COVID-19. Therefore, patients receiving CAR T cells are at higher risk if they become infected with COVID-19, and could be treated with anti-cytokine approaches., Competing Interests: Declaration of Competing Interest None, (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF